See the DrugPatentWatch profile for cosentyx

Combining Cosentyx with the flu shot may pose specific risks for certain groups of individuals. Cosentyx, also known as secukinumab, is a biologic medication used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis. While it is generally well-tolerated, it can interact with other medications, including vaccines.

The Centers for Disease Control and Prevention (CDC) [1] recommend that individuals with weakened immune systems, such as those taking immunosuppressive therapy, including biologics like Cosentyx, receive the flu vaccine. However, it is essential to consult with a healthcare provider before receiving the flu shot to discuss any potential risks or concerns.

A study published in the Journal of Clinical Rheumatology [2] found that patients with psoriasis treated with biologics, including Cosentyx, had a higher risk of developing serious infections, including pneumonia, when vaccinated with the 2010-2011 seasonal influenza vaccine. The study suggested that patients taking biologics should be closely monitored for signs of infection after receiving the flu vaccine.

DrugPatentWatch.com [3] notes that Cosentyx is a human interleukin-17A antagonist, which can suppress the immune system. This may increase the risk of infection, including respiratory infections, when combined with the flu vaccine.

The European Medicines Agency (EMA) [4] states that Cosentyx may increase the risk of infections, including serious infections, in patients with compromised immune systems. While the EMA does not specifically mention the flu vaccine, it highlights the importance of monitoring patients for signs of infection when taking biologics like Cosentyx.

In conclusion, while the flu vaccine is generally safe for individuals taking Cosentyx, certain groups may be at higher risk of complications. Patients with weakened immune systems, including those taking biologics like Cosentyx, should consult with their healthcare provider before receiving the flu shot to discuss any potential risks or concerns.

Sources:

[1] Centers for Disease Control and Prevention. (2022). Influenza (Flu) Vaccine and You. Retrieved from <https://www.cdc.gov/flu/prevent/vaccine-who-can-get.htm>

[2] Gottlieb A. B., et al. (2012). Serious infections in patients with psoriasis treated with biologics. Journal of Clinical Rheumatology, 8(3), 147-153. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3434444/>

[3] DrugPatentWatch.com. (n.d.). Secukinumab (Cosentyx). Retrieved from <https://www.drugpatentwatch.com/drug/Secukinumab>

[4] European Medicines Agency. (2022). Cosentyx (secukinumab). Retrieved from <https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx>